Trump Unveils TrumpRx to Sell Prescription Drugs Direct to Consumers

President Donald Trump is poised to unveil a new direct-to-consumer pharmaceutical platform called TrumpRx, designed to let Americans purchase prescription drugs online from manufacturers at government-negotiated discounts. The initiative would bypass some traditional intermediaries and aim to reduce costs for patients.

In parallel, Trump announced a deal with Pfizer under which the company will lower the prices of its drugs sold through Medicaid and commit to a $70 billion investment in domestic research, manufacturing, and development. Through TrumpRx, Pfizer is expected to sell certain products directly to consumers at prices aligned with the administration’s “most favored nation” pricing policy.

While supporters argue the move will increase pricing transparency and help shift market dynamics, skeptics caution it may face logistical, regulatory, and legal hurdles. Questions remain about how insurance providers will respond, how the platform will integrate with existing pharmacy networks, and whether other drugmakers will participate.

The broader push reflects Trump’s intensified campaign to contend with high drug costs, including new directives to the FDA and HHS to crack down on misleading direct-to-consumer pharmaceutical advertising.